Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Subtle Medical

    • Home
    • Subtle Medical
Company Medical Device

Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform

Fineline Cube Feb 24, 2025

Shanghai-based Subtle Medical Inc., an AI-powered medical imaging firm operating in the U.S. and China,...

Company Deals Medical Device

Subtle Medical Inc Closes USD 10 Million Series B+ Round to Accelerate Global Expansion

Fineline Cube May 13, 2024

Subtle Medical Inc, a medical imaging specialist and Stanford University spin-off, has reportedly raised close...

Company Deals

Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging

Fineline Cube Nov 17, 2022

Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised...

Recent updates

  • Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
  • Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures
  • Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes
  • Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
  • TransThera Tinengotinib Cholangiocarcinoma Priority Review China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.